The serum biomarker cancer antigen 125 (CA125) is widely used in countries around the world, including the United States, Australia, Canada, and Ireland, as an investigation for ovarian cancer in symptomatic women presenting to primary care [7]. Here, MUC16 is linked to ovarian carcinoma.